Atticus Wealth Management, LLC Gilead Sciences, Inc. Transaction History

Atticus Wealth Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	SELL	$62.32 - $89.47 $5,359 - $7,694	-86 Reduced 89.58%	10 $0
Q2 2022 Jul 13, 2022	BUY	$57.72 - $65.01 $2,886 - $3,250	50 Added 108.7%	96 $6,000
Q1 2022 Apr 15, 2022	BUY	$57.92 - $72.58 $2,085 - $2,612	36 Added 360.0%	46 $3,000
Q4 2021 Jan 26, 2022	SELL	$64.88 - $73.64 $713 - $810	-11 Reduced 52.38%	10 $1,000
Q3 2021 Oct 18, 2021	SELL	$67.69 - $73.03 $209,839 - $226,393	-3,100 Reduced 99.33%	21 $1,000
Q2 2021 Jul 21, 2021	BUY	$63.47 - $69.35 $825 - $901	13 Added 0.42%	3,121 $215,000
Q1 2021 Apr 15, 2021	SELL	$60.0 - $68.46 $4,200 - $4,792	-70 Reduced 2.2%	3,108 $201,000
Q4 2020 Jan 20, 2021	BUY	$56.65 - $64.55 $2,322 - $2,646	41 Added 1.31%	3,178 $185,000
Q3 2020 Oct 21, 2020	BUY	$62.1 - $78.08 $8,383 - $10,540	135 Added 4.5%	3,137 $198,000
Q2 2020 Jul 15, 2020	BUY	$72.34 - $84.0 $651 - $756	9 Added 0.3%	3,002 $231,000
Q1 2020 Apr 23, 2020	BUY	$62.63 - $80.22 $145,740 - $186,671	2,327 Added 349.4%	2,993 $224,000
Q4 2019 Feb 03, 2020	BUY	$61.62 - $67.78 $41,038 - $45,141	666 New	666 $43,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Atticus Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Atticus Wealth Management, LLC with notifications on news.